ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

NITE Nightstar Therapeutics Plc ADS

25.41
0.00 (0.00%)
Last Updated: 01:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type
Nightstar Therapeutics Plc ADS NASDAQ:NITE NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 25.41 18.50 25.41 0 01:00:00

Nasdaq Welcomes Nightstar Therapeutics Nightstar plc (Nasdaq: NITE) to The Nasdaq Stock Market

28/09/2017 11:03pm

GlobeNewswire Inc.


Nightstar Therapeutics Plc ADS (NASDAQ:NITE)
Historical Stock Chart


From Jul 2019 to Jul 2024

Click Here for more Nightstar Therapeutics Plc ADS Charts.

Nightstar Therapeutics plc (Nasdaq:NITE), a leading clinical-stage gene therapy company, rang the closing bell at the Nasdaq MarketSite in Times Square today in celebration of its initial public offering (IPO) on The Nasdaq Stock Market.

Nightstar Therapeutics plc (Nasdaq:NITE), a leading clinical-stage gene therapy company focused on novel one-time treatments for patients suffering from rare inherited retinal diseases that would otherwise progress to blindness, visits the Nasdaq MarketSite in Times Square in celebration of its initial public offering (IPO).
Nightstar Therapeutics (Nasdaq:NITE) Rings The Nasdaq Stock Market Closing Bell in Celebration of It's IPO.

Photos accompanying this announcement are available at

http://www.globenewswire.com/NewsRoom/AttachmentNg/f735cbc8-df61-417e-9a3a-3dee84c8a5ed

http://www.globenewswire.com/NewsRoom/AttachmentNg/ea0abfbd-e1c2-43e7-9091-8d8c86fb60ce

Nightstar Therapeutics focuses on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases that would otherwise progress to blindness. Through their expertise in ophthalmology, gene therapy and drug development, they are developing a pipeline of proprietary product candidates that are designed to substantially modify or halt the progression of inherited retinal diseases for which there are no currently approved treatments.

“Nightstar Therapeutics continues to innovate in life changing treatments,” said Nelson Griggs, President of the Nasdaq Stock Exchange, “We are extremely proud to partner with them as they continue to break barriers in the health care sector as a public company.”

The information contained above is provided for informational and educational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. Information about the company is provided by the company or comes from the company’s public filings and is not independently verified by Nasdaq.  Neither Nasdaq nor any of its affiliates makes any recommendation to buy or sell any security or any representation about the financial condition of any company. Statements regarding Nasdaq-listed companies are not guarantees of future performance. Actual results may differ materially from those expressed or implied. Past performance is not indicative of future results. Investors should undertake their own due diligence and carefully evaluate companies before investing. ADVICE FROM A SECURITIES PROFESSIONAL IS STRONGLY ADVISED.

About NasdaqNasdaq (Nasdaq:NDAQ) is a leading global provider of trading, clearing, exchange technology, listing, information and public company services. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 90 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to approximately 3,900 total listings with a market value of approximately $12 trillion. To learn more, visit: http://business.nasdaq.com.

Media Relations Contacts:Stephanie Lowenthal(646) 441-5073Stephanie.Lowenthal@nasdaq.com

Emily Pan(646) 441-5120emily.pan@nasdaq.com

- NDAQG -

1 Year Nightstar Therapeutics Plc ADS Chart

1 Year Nightstar Therapeutics Plc ADS Chart

1 Month Nightstar Therapeutics Plc ADS Chart

1 Month Nightstar Therapeutics Plc ADS Chart

Your Recent History

Delayed Upgrade Clock